Helping Biotron to Do Better and Deliver Tangible Results: Shareholders Call for ASIC Action and Regulatory Scrutiny, page-200

I watched it. Lights are on till at least 2026, I presume early 2026. Expenditure is roughly $125k a month.

HepB is to be animal model trial, costing $50,000. This could add interest apparently. US company is collaborating.
My 57m in losses question was answered. The buyer would have to be a biotech in a similar field. Seeing most big Pharma that they approach are, then I presume, that could be possible.
There will be a R&D refund coming said MM.
Basically we wait, MM is in constant contact with C14. No details can be given, commercial in confidence.

Management is confident.